Which has preferable earnings & valuation, PPBT or JSPR?

Purple Biotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Purple Biotech N/A N/A -$26.39M -$18.84 N/A Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A

Is PPBT or JSPR more profitable?

Purple Biotech's return on equity of -123.63% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -123.63% -98.72% Jasper Therapeutics N/A -613.51% -162.52%

Which has better valuation and earnings, PPBT or INAB?

IN8bio is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Purple Biotech N/A N/A -$26.39M -$18.84 N/A IN8bio N/A N/A -$19.44M -$2.61 N/A

Is PPBT or INAB more profitable?

IN8bio's return on equity of -96.39% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -123.63% -98.72% IN8bio N/A -96.39% -80.18%

Is PPBT or LEXX more profitable?

Purple Biotech's return on equity of -123.63% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -123.63% -98.72% Lexaria Bioscience N/A -206.02% -162.53%

Do analysts prefer BLRX or PPBT?

Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 913.51%. Given Purple Biotech's higher possible upside, analysts clearly believe Purple Biotech is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BLRX or PPBT more profitable?

Purple Biotech has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -563.70% -37.73% -19.42% Purple Biotech N/A -123.63% -98.72%

Which has preferable valuation & earnings, COCP or PPBT?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A Purple Biotech N/A N/A -$26.39M -$18.84 N/A

Is COCP or PPBT more profitable?

Purple Biotech's return on equity of -123.63% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Purple Biotech N/A -123.63% -98.72%

Purple Biotech (PPBT) Competitors

$2.96 -0.03 (-1.00%)

Closing price 06/10/2026 04:00 PM Eastern

Extended Trading

$2.84 -0.12 (-4.05%)

As of 06/10/2026 07:42 PM Eastern

Compare

PPBT vs. JSPR, INAB, LEXX, BLRX, and COCP

Should you buy Purple Biotech stock or one of its competitors? MarketBeat compares Purple Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Purple Biotech include Jasper Therapeutics (JSPR), IN8bio (INAB), Lexaria Bioscience (LEXX), BioLineRx (BLRX), and Cocrystal Pharma (COCP). These companies are all part of the "pharmaceutical products" industry.

How does Purple Biotech compare to Jasper Therapeutics?

Purple Biotech (NASDAQ:PPBT) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Purple Biotech currently has a consensus price target of $30.00, suggesting a potential upside of 913.51%. Jasper Therapeutics has a consensus price target of $13.14, suggesting a potential upside of 2,730.68%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Purple Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jasper Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Purple Biotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

Purple Biotech's return on equity of -123.63% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
Jasper Therapeutics	N/A	-613.51%	-162.52%

Purple Biotech has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3, meaning that its share price is 200% more volatile than the broader market.

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 3.0% of Purple Biotech shares are held by insiders. Comparatively, 4.6% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Purple Biotech and Purple Biotech both had 2 articles in the media. Jasper Therapeutics' average media sentiment score of 0.63 beat Purple Biotech's score of 0.44 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Purple Biotech	Neutral
Jasper Therapeutics	Positive

Summary

Jasper Therapeutics beats Purple Biotech on 9 of the 12 factors compared between the two stocks.

How does Purple Biotech compare to IN8bio?

Purple Biotech (NASDAQ:PPBT) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Purple Biotech has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, IN8bio has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

In the previous week, Purple Biotech and Purple Biotech both had 2 articles in the media. IN8bio's average media sentiment score of 0.77 beat Purple Biotech's score of 0.44 indicating that IN8bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Purple Biotech	Neutral
IN8bio	Positive

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Purple Biotech currently has a consensus target price of $30.00, indicating a potential upside of 913.51%. IN8bio has a consensus target price of $4.00, indicating a potential upside of 185.71%. Given Purple Biotech's higher probable upside, research analysts plainly believe Purple Biotech is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IN8bio is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

IN8bio's return on equity of -96.39% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
IN8bio	N/A	-96.39%	-80.18%

Summary

IN8bio beats Purple Biotech on 7 of the 10 factors compared between the two stocks.

How does Purple Biotech compare to Lexaria Bioscience?

Purple Biotech (NASDAQ:PPBT) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Purple Biotech currently has a consensus target price of $30.00, suggesting a potential upside of 913.51%. Lexaria Bioscience has a consensus target price of $1.50, suggesting a potential upside of 128.66%. Given Purple Biotech's higher probable upside, research analysts plainly believe Purple Biotech is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Purple Biotech has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

In the previous week, Purple Biotech had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Lexaria Bioscience. Purple Biotech's average media sentiment score of 0.44 beat Lexaria Bioscience's score of 0.37 indicating that Purple Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Purple Biotech	Neutral
Lexaria Bioscience	Neutral

Lexaria Bioscience has higher revenue and earnings than Purple Biotech. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
Lexaria Bioscience	$710K	22.90	-$11.90M	-$0.47	N/A

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Purple Biotech's return on equity of -123.63% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
Lexaria Bioscience	N/A	-206.02%	-162.53%

Summary

Purple Biotech beats Lexaria Bioscience on 7 of the 12 factors compared between the two stocks.

How does Purple Biotech compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Purple Biotech has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
Purple Biotech	N/A	-123.63%	-98.72%

BioLineRx has higher revenue and earnings than Purple Biotech. BioLineRx is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	12.15	-$1.17M	-$1.92	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

BioLineRx has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 913.51%. Given Purple Biotech's higher possible upside, analysts clearly believe Purple Biotech is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Purple Biotech had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 1.12 beat Purple Biotech's score of 0.44 indicating that BioLineRx is being referred to more favorably in the media.

Company	Overall Sentiment
BioLineRx	Positive
Purple Biotech	Neutral

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

BioLineRx beats Purple Biotech on 7 of the 13 factors compared between the two stocks.

How does Purple Biotech compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Cocrystal Pharma has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

In the previous week, Purple Biotech had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Cocrystal Pharma. Purple Biotech's average media sentiment score of 0.44 beat Cocrystal Pharma's score of 0.29 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Purple Biotech	Neutral

Purple Biotech's return on equity of -123.63% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Purple Biotech	N/A	-123.63%	-98.72%

Cocrystal Pharma currently has a consensus price target of $6.00, indicating a potential upside of 500.00%. Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 913.51%. Given Purple Biotech's higher probable upside, analysts clearly believe Purple Biotech is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Purple Biotech beats Cocrystal Pharma on 6 of the 11 factors compared between the two stocks.

Get Purple Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPBT vs. The Competition

Export

Metric	Purple Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.84M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.32%	2.67%	5.61%
P/E Ratio	-0.16	18.83	24.41	23.63
Price / Sales	N/A	296.01	502.24	103.14
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	0.39	8.00	10.43	6.70
Net Income	-$26.39M	$23.89M	$3.56B	$337.26M
7 Day Performance	-4.21%	-5.43%	-2.94%	-2.43%
1 Month Performance	-27.09%	-4.18%	-0.39%	0.19%
1 Year Performance	-88.44%	36.70%	20.10%	23.15%

Purple Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPBT Purple Biotech	3.2299 of 5 stars	$2.96 -1.0%	$30.00 +913.5%	-88.8%	$3.84M	N/A	N/A	20	Short Interest Increase
JSPR Jasper Therapeutics	3.2243 of 5 stars	$0.55 +3.2%	$13.14 +2,284.0%	-92.0%	$15.44M	N/A	N/A	20	Gap Up High Trading Volume
INAB IN8bio	3.7958 of 5 stars	$1.56 -9.8%	$4.00 +156.4%	-51.4%	$15.37M	N/A	N/A	20	Short Interest Decrease Gap Down
LEXX Lexaria Bioscience	2.1791 of 5 stars	$0.60 -2.5%	$1.50 +149.6%	-37.5%	$14.90M	$368K	N/A	7	Positive News Gap Down
BLRX BioLineRx	1.1056 of 5 stars	$3.39 -2.6%	N/A	-43.6%	$14.81M	$1.18M	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPBT) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Purple Biotech (PPBT) Competitors

PPBT vs. JSPR, INAB, LEXX, BLRX, and COCP

How does Purple Biotech compare to Jasper Therapeutics?

Summary

How does Purple Biotech compare to IN8bio?

Summary

How does Purple Biotech compare to Lexaria Bioscience?

Summary

How does Purple Biotech compare to BioLineRx?

Summary

How does Purple Biotech compare to Cocrystal Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Purple Biotech (PPBT) Competitors

PPBT vs. JSPR, INAB, LEXX, BLRX, and COCP

How does Purple Biotech compare to Jasper Therapeutics?

Do analysts rate PPBT or JSPR?

Which has preferable earnings & valuation, PPBT or JSPR?

Is PPBT or JSPR more profitable?

Which has more risk and volatility, PPBT or JSPR?

Do insiders & institutionals hold more shares of PPBT or JSPR?

Does the media prefer PPBT or JSPR?

Summary

How does Purple Biotech compare to IN8bio?

Which has more volatility & risk, PPBT or INAB?

Does the media favor PPBT or INAB?

Do insiders and institutionals hold more shares of PPBT or INAB?

Do analysts prefer PPBT or INAB?

Which has better valuation and earnings, PPBT or INAB?

Is PPBT or INAB more profitable?

Summary

How does Purple Biotech compare to Lexaria Bioscience?

Do analysts recommend PPBT or LEXX?

Which has more risk and volatility, PPBT or LEXX?

Does the media favor PPBT or LEXX?

Which has higher earnings & valuation, PPBT or LEXX?

Do insiders & institutionals believe in PPBT or LEXX?

Is PPBT or LEXX more profitable?

Summary

How does Purple Biotech compare to BioLineRx?

Is BLRX or PPBT more profitable?

Which has stronger earnings & valuation, BLRX or PPBT?

Which has more volatility & risk, BLRX or PPBT?

Do analysts prefer BLRX or PPBT?

Does the media favor BLRX or PPBT?

Do insiders and institutionals have more ownership in BLRX or PPBT?

Summary

How does Purple Biotech compare to Cocrystal Pharma?

Which has more volatility and risk, COCP or PPBT?

Do institutionals and insiders believe in COCP or PPBT?

Which has preferable valuation & earnings, COCP or PPBT?

Does the media refer more to COCP or PPBT?

Is COCP or PPBT more profitable?

Do analysts rate COCP or PPBT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools